Case Presentation

Primary cutaneous follicle-center lymphoma

Ian M. Ahearn MD PhD, Stephanie W. Hu MD, Shane A. Meehan MD, and Jo-Ann Latkowski MD

Dermatology Online Journal 20 (12): 1

New York University School of Medicine

Special Guest Editor: Nicholas A. Soter, MD

Abstract

We present a 64-year-old man with a three-year history of pruritic, pink papules and nodules of the face who was found to have a clonal lymphoproliferative B-cell disease that was characterized by a clonal IGH rearrangement. Although morphologic features present in the biopsy specimen were consistent with a reactive process, additional clinicopathologic correlation (anatomic presentation of lesions on the face, the absence of t(14:18) translocation, and bel-2 and MUM1 expression) reinforced suspicion of a cutaneous B-cell lymphoma. Systemic work-up with CT/PET and a bone marrow biopsy ultimately excluded systemic disease and primary cutaneous follicle-center lymphoma (PCFCL) was a strong diagnostic consideration. The patient was treated with systemic rituximab with a partial resolution of the facial lesions. The case demonstrates both clinical and pathologic challenges to the diagnosis of primary cutaneous B-cell lymphoma (PCBCL). Furthermore, despite a newly refined classification system, the case also specifically highlights the persistent requirement for flexible clinical reasoning and pathologic correlation. Such reasoning is necessary to generate individualized strategies for diagnosis and treatment when cutaneous B-cell lymphoma is suspected.
Case synopsis

History: A 63-year-old man presented to the Manhattan Campus of VA New York Harbor Healthcare System for treatment of pruritic papules and nodules on the face. The patient, originally from Puerto Rico, lived in the New York. He initially presented to the Dermatology Clinic in February, 2010, with a one-month history of papules and nodules on the forehead and temple. Metronidazole gel and hydrocortisone cream were prescribed with no improvement. A punch biopsy specimen of the left cheek showed granulomatous inflammation. Over the subsequent 18 months, the patient was managed for a presumptive diagnosis of granulomatous rosacea with oral and topical medications, which included topical metronidazole gel, topical tacrolimus ointment, topical clindamycin, oral doxycycline, oral minocycline, topical dapsone, topical crotamiton, topical permethrin, and sulfacetamide/sulfur lotion. Despite these interventions, he experienced an increasing number of facial lesions and pruritus. A second biopsy of the right cheek showed a reactive lymphocytic infiltrate with germinal centers and prominent blood vessels with plump endothelial cells. The possibility of angiolymphoid hyperplasia with eosinophilia was raised. Review of this specimen noted a dense, nodular, lymphohistocytic infiltrate within the dermis, and the possibility of a pseudolymphoma also was raised. The findings were, nonetheless, considered consistent with the clinical diagnosis of granulomatous rosacea.

Past medical history included depression. He denied any systemic symptoms, which included fever, chills, night sweats, or weight loss. The patient pursued a second opinion at the Bronx Campus of VA New York Harbor Healthcare System Dermatology Clinic and a repeat punch biopsy of the cheek was performed.

Physical examination: There were multiple, erythematous, 1 to 2-cm, pink-to-purple, indurated plaques and nodules over the right and left preauricular skin. There was no cervical, submental, posterior auricular, occipital, axillary, or inguinal lymphadenopathy.

Laboratory: A complete blood count and chemistry profile were normal. A positron emission tomography/computed tomography scan and a bone marrow biopsy specimen did not show disease.

Histopathology: There is a dense, nodular, lymphoid infiltrate in the dermis without appreciable epidermotropism. The nodules appear to be well-defined follicles, which show a predominance of lymphocytes in addition to tingible body macrophages and scattered eosinophils. Immunostains show that the lymphocytes are mostly follicle-center B cells, which are positive for CD20, Pax5, CD10, and Bcl-6, but are negative for Bcl-2. Ki-67 shows a high proliferative rate. Per report, a clonal B-cell population was detected upon PCR analysis for immunoglobulin heavy-chain gene rearrangement.

Discussion

Diagnosis: Primary cutaneous follicle-center lymphoma, likely
Genetic translocations that are found in PCMZL include t(14;18) in <25% of cases [8,9]. Less commonly t(11;18) and t(3;14)

PCMZL commonly presents as red-to-violaceous papules, nodules, or plaques on the face, trunk, and arms. Differential diagnosis include dermal and subcutaneous nodular-to-diffuse marginal zone B-cells, lymphoplasmacytoid mononuclear cells, evident plasma of PCMZL often includes urticaria, leukemia cutis, pseudolymphoma, and insect bites. Histopathologic features of PCMZL only location.

Has a poor prognosis, PET/CT and bone marrow biopsy, only in cases where PET/CT is positive, is indicated to verify its skin-only location.

Clinically, PCFCL commonly presents as pink-to-violaceous nodules and plaques on the head and neck. The differential diagnosis commonly includes rosacea, folliculitis, acne, insect bites, merkel-cell carcinoma, cutaneous lymphoid hyperplasia, and basal-cell carcinoma. Histopathologic features of PCFCL include dermal and subcutaneous proliferations of CD20+ centrocytes and centroblasts, either in follicular or diffuse growth patterns [1-3]. Early lesions of PCFCL often show a perivascular or periadnexal, lymphocytic infiltrate and often are mistaken for pseudolymphoma initially. PCFCL is notable for an absence of Bcl-2, MUM1/IRF4, and FOX-P1. Malignant B-cells in PCFCL do not harbor the t(14:18) translocation that is commonly observed in the nodal variant form of this disease. PCFCL carries a favorable prognosis with a 95% five-year survival; prognosis is not affected by histopathologic growth pattern or the presence of multifocal lesions [3-5]. Because nodal follicle center lymphoma has a poor prognosis, PET/CT and bone marrow biopsy, only in cases where PET/CT is positive, is indicated to verify its skin-only location.

PCMZL commonly presents as red-to-violaceous papules, nodules, or plaques on the face, trunk, and arms. Differential diagnosis of PCMZL often includes urticaria, leukemia cutis, pseudolymphoma, and insect bites. Histopathologic features of PCMZL include dermal and subcutaneous nodular-to-diffuse marginal zone B-cells, lymphoplasmacytoid mononuclear cells, evident plasma cells, centro/immunoblast-like cells, and reactive T-cells [1-3]. Malignant cells are CD20+, Bcl-2+, and MUM-1/IRF4+ [6,7]. Genetic translocations that are found in PCMZL include t(14;18) in <25% of cases [8,9]. Less commonly t(11;18) and t(3;14) translocation are observed as well. PCMZL also carries a very good prognosis with a 99% five-year survival rate [3].

PCDLBCL-leg presents as red-to-blue nodules or plaques on the lower extremities. Like PCFCL, PCDLBCL-leg also is of follicular origin and is composed of large B-cells with a diffuse dermal growth of centroblasts and immunoblasts [1-3]. In contrast to PCFCL, the malignant B-cells in PCDLBCL-leg express MUM1/IRF4, FOX-P1, IgM, and bcl-2 [10,11]. Although the t(14;18) translocation is not present characteristically, many other chromosomal aberrations are common [12-14]. Prognosis associated with PCDLBCL-leg is less favorable, with studies demonstrating a 50% 5-year survival rate [15,16]. This striking survival difference makes the distinction of PCDLBCL-leg from PCFCL of utmost importance. Under the WHO-EORTC classification, criteria are available to properly classify PCFCL and PCDLBCL-leg using clinical, histopathologic, genetic, and immunophenotypic methods. Classification then may better inform clinicians regarding optimal treatment strategies and prognosis.

For the patient presented, the anatomic distribution of facial nodules and plaques, with an evident follicular pattern growth and the absence of bcl-2, t(14;18), and MUM-1 expression were demonstrated. However, histopathologic review showed prominent features that were consistent with a reactive lymphocytic process or pseudolymphoma. After identification of a monoclonal IgH rearrangement via PCR, a cutaneous B-cell lymphoma could not be excluded. Subsequent systemic evaluation with PET/CT and a bone marrow biopsy specimen did not show evidence of extracutaneous disease. In this scenario, PCFCL remained a strong consideration. The patient underwent treatment with intravenous rituximab with partial resolution.

This case highlights the challenging pathobiologic aspects of cutaneous lymphoproliferative processes, but the clinical presentation that was consistent with a reactive lymphocytic process or pseudolymphoma. After identification of a monoclonal IgH rearrangement via PCR, a cutaneous B-cell lymphoma could not be excluded. Subsequent systemic evaluation with PET/CT and a bone marrow biopsy specimen did not show evidence of extracutaneous disease. In this scenario, PCFCL remained a strong consideration. The patient underwent treatment with intravenous rituximab with partial resolution.
References

1. Willemze, R, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768 [PMID: 15692063]
2. Suarez, AL, et al. Primary cutaneous B-Cell lymphomas. J Am Acad Derm 2013; 69: 329. [PMID: 23957985]
3. Willemze, R, et al. EORTC classification for primary cutaneous lymphomas: a proposal for the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer (EORTC). Blood 1997; 90: 354 [PMID: 9207472]
4. Grange F, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19: 3602 [PMID: 11504742]
5. Bekkenk MW, et al. Treatment of multifocal primary cutaneous B-cell lymphomas: a European multicenter study. J Clin Onc 1999; 17: 2471 [PMID: 10561311]
6. de Leval, L, et al. Cutaneous B-cell lymphomas of follicular and marginal cell types: use of Bcl-6, CD10, Bcl-2 and CD21 in differential diagnosis and classification. Am J Surg Pathol 2001; 25: 732 [PMID: 11395550]
7. Hoefnagel JJ, et al. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol 2003; 149: 1183 [PMID: 14674895]
8. Streubel B, et al. T(14;18) (q23;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 2003; 101: 233. [PMID: 12406890]
9. Schreuder MI, et al. FISH analysis of MALT lymphoma specific translocations and aneuploidy in primary cutaneous marginal cell lymphoma. J Pathol 2005; 205: 305. [PMID: 15682432]
10. Grange F, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol 2007; 143: 1144 [PMID: 17875875]
11. Grange F, et al. Bcl-2 expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood 2004; 103: 3662. [PMID: 14726400]
12. Hallerman C, et al. Cytogenetic aberration patterns differ in subtypes of primary cutaneous B-cell lymphomas. J Invest Dermatol 2004; 122: 1495 [PMID:15175042]
13. Hallerman C, et al. Molecular cytogenetic analysis of chromosomal breakpoints in IGH, MYC, BCL6 and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol 2004; 123: 213 [PMID: 15191563]
14. Hoefnagel JJ, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005; 105: 3671 [PMID: 15308563]
15. Vermeer MH, et al. Primary cutaneous B-cell lymphomas of the legs: a distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Arch Dermatol 1996; 126: 1304 [PMID: 8915307]
16. Grange F, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19: 3602 [PMID: 11504742]
17. Barzilai A, et al. Cutaneous B-Cell neoplasms mimicking granulomatous rosacea or rhinophyma. Arch Dermatol 2012; 148: 824 [PMID: 22508769]